Drugs / ChAdOx1-HBV
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04297917 | Feb 2019 → May 2022 | hepatitis B virus infection | Barinthus Biotherapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04778904 | Dec 2020 → Feb 2023 | chronic hepatitis B virus infection | Barinthus Biotherapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05343481 | Sep 2022 → Jan 2026 | chronic hepatitis B virus infection | Barinthus Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1-HBV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05343481 ↗ |
| Modality | Vaccine | “therapeutic vaccine ChAdOx1-HBV” PMID 37791379 ↗ Aug 2023 |
| Route | Intramuscular | “Each participant received 1 dose of the vaccine (intramuscular injection).” NCT04297917 ↗ |